abituzumab + cetuximab + irinotecan

Abituzumab + cetuximab + irinotecan is an investigational combination therapy evaluated primarily for the treatment of metastatic colorectal cancer (mCRC), particularly in patients with KRAS wild-type tumors. Abituzumab (EMD 525797) is a humanized monoclonal IgG2 antibody that targets integrin αv heterodimers, notably αvβ5 and αvβ6 integrins, which are implicated in tumor progression and metastasis. Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting downstream signaling involved in cell proliferation and survival. Irinotecan is a small molecule chemotherapeutic agent that inhibits topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing cells. The combination has been studied in phase I/II clinical trials as second-line therapy for patients with KRAS wild-type mCRC who have progressed after oxaliplatin-containing regimens. The rationale for combining these agents lies in their complementary mechanisms—targeting both integrin-mediated tumor microenvironment interactions and EGFR-driven signaling pathways while providing cytotoxic chemotherapy[1][3][4].